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Background: Mechanisms underlying the 
cardioprotective profile of G-protein-coupled 
receptor kinase 2 (GRK2) inhibitors are 
incompletely understood. 
Results: GRK2 inhibition activated the growth-
promoting MAPK pathway, which contributed 
to cardioprotection by preventing cardiomyocyte 
death. 
Conclusion: Cardioprotective activity of GRK2 
inhibitors overlaps with enhanced tumor growth. 
Significance: A promising class of kinase 
inhibitors for heart failure treatment shows 
overlapping of cardioprotective signaling with 
tumor growth promotion. 
 
SUMMARY 
Inhibition of G-protein-coupled 
receptor kinase 2 (GRK2) is an emerging 
treatment option for heart failure. Because 
GRK2 is also indispensable for growth and 
development, we analyzed the impact of 
GRK2 inhibition on cell growth and 
proliferation. Inhibition of GRK2 by the 
dominant-negative GRK2-K220R did not 
affect the proliferation of cultured cells. In 
contrast, upon xenograft transplantation of 
cells into immunodeficient mice, the 
dominant-negative GRK2-K220R or a GRK2-
specific peptide inhibitor increased tumor 
mass. The enhanced tumor growth upon 
GRK2 inhibition was attributed to the 
growth-promoting MAPK pathway because 
dual inhibition of the GRK2 and RAF-MAPK 
axis by the Raf kinase inhibitor protein 
(RKIP) did not increase tumor mass. The 
MAPK cascade contributed to the 
cardioprotective profile of GRK2 inhibition 
by preventing cardiomyocyte death whereas 
dual inhibition of RAF/MAPK and GRK2 by 
RKIP induced cardiomyocyte apoptosis, 
cardiac dysfunction and signs of heart failure. 
Thus, cardioprotective signaling induced by 
GRK2 inhibition is overlapping with tumor 
growth promotion. 
G-protein-coupled receptor kinases, 
GRKs, were initially characterized as a family of 
kinases, which promote the desensitization of G-
protein-coupled receptors (GPCRs) by receptor 
phosphorylation and subsequent (β-)arrestin-
mediated uncoupling of the receptor from the 
heterotrimeric G-protein (1). Among different 
members of the GRK family, GRK2 has a 
unique role in the control of growth and 
development (2,3), and individuals lacking 
GRK2 are not viable (3,4). The growth-
promoting activity of GRK2 in vivo was 
attributed to kinase-dependent and kinase-
independent effects of GRK2 involving 
Smoothened and Patched homolog 1 (2,3).  
Apart from its essential physiological 
role in growth and development, exaggerated 
GRK2 activity is an important 
pathophysiological feature of cardiovascular 
diseases such as hypertension and heart failure 
(5,6). Under such conditions of increased GRK2 
activity, GRK2 inhibition confers cardio-
protection (7). Therefore many research efforts 
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focus on the development and characterization 
of GRK2-specific inhibitors (7-9).  
A common approach of GRK2 
inhibition in vivo relies on expression of the 
carboxyl terminal domain of GRK2, i.e. the 
betaARK1ct (GRK2ct), which inhibits 
membrane translocation and activation of GRK2 
by scavenging Gβγ subunits of heterotrimeric G-
proteins (10-12). However, neutralization of Gβγ 
subunits by the GRK2ct may also exert GRK2-
independent effects, which could contribute to 
cardioprotection as well (13). The final “proof-
of-concept” for a beneficial profile of GRK2 
inhibition came from studies applying mice with 
cardiac-specific deletion of GRK2 where GRK2 
deficiency protected against myocardial damage 
(14) and prevented adverse remodeling after 
myocardial infarction (15). 
While the beneficial cardiac profile of 
GRK2 inhibition is thus firmly established, 
mechanisms underlying cardio-protection are not 
fully understood. Because growth-regulatory 
pathways are essential for cardiomyocyte 
survival (16,17), we considered the impact of 
GRK2 inhibition on cell growth and 
proliferation. However, the role of GRK2 in cell 
growth and proliferation is not clear, because in 
addition to the above-mentioned growth-
promoting activity, GRK2 can also exert growth 
inhibition leading to suppressed growth and 
proliferation of tumor cells (18,19). 
To address the role of GRK2 and GRK2 
inhibition in cell growth and proliferation, we 
performed experiments with cultured cells, or 
expanded cells in vivo after xenograft 
transplantation into immunodeficient non-obese 
diabetic mice homozygous for the severe 
combined immune deficiency spontaneous 
mutation (NOD.Scid mice). Systemic effects of 
GRK2 inhibition were also analyzed in vivo with 
transgenic mice expressing a GRK2-specific 
peptide inhibitor under control of the human 
cytomegalovirus (CMV) immediate-early 
promoter/enhancer, which directs ubiquitous 
expression of a transgene. Furthermore, 
transgenic mice with myocardium-specific 
expression of GRK2 inhibitors were generated to 
assess their cardio-protective profile. We report 
here that GRK2 inhibition triggered the growth-
promoting MAPK pathway, which promoted 
tumor growth but also conferred 
cardioprotection by preventing cardiomyocyte 
death. 
 
 
EXPERIMENTAL PROCEDURES 
Generation of transgenic mice - To generate 
mice with myocardium-specific over-expression 
of RKIP, a transgene placing the PEBP1 cDNA 
under control of the α-myosin heavy chain (α-
MHC) promoter (20) was constructed. For 
myocardium-specific expression of the GRK2-
specific peptide inhibitor (GRK-Inh), a DNA 
fragment encoding the peptide sequence, 
MAKFERLQTVTNYFITSE (21,22), was inserted 
into the Alpha-MyHC plasmid. The plasmid 
sequences were removed by NotI digestion, and 
the purified linear DNA (2ng/µl) was injected 
into fertilized oocytes of superovulated B6 
(C57BL/6J) and FVB (FVB/N) mice. Oviduct 
transfer of the injected embryos into 
pseudopregnant CD-1 mice was performed 
according to standard procedures (23). Genomic 
DNA of the F0 generation was isolated from ear 
punch biopsies taken at 3-4 weeks of age and 
analyzed by PCR for integration of the 
transgene. Mice of two different transgenic lines 
each were born at Mendelian frequency and 
grew to adulthood normally. 
To assess the systemic effect of GRK2 
inhibition by the GRK2-specific peptide 
inhibitor in vivo, we generated transgenic mice 
with expression of the GRK2-specific peptide 
inhibitor under control of the CMV immediate-
early promoter/enhancer, which directs 
ubiquitous expression of a transgene. To 
generate CMV-GRK-Inh-transgenic mice, the 
DNA fragment encoding the peptide sequence, 
MAKFERLQTVTNYFITSE, was inserted into the 
pcDNA3.1 plasmid (Invitrogen). Plasmid 
sequences were removed by MluI and DraIII 
digestion, and the purified linear DNA (2ng/µl) 
was injected into fertilized oocytes of 
superovulated B6 and FVB mice. Oviduct 
transfer of the injected embryos into 
pseudopregnant CD-1 mice and all subsequent 
steps were performed as detailed above. 
Cell culture and in vivo cell expansion 
in NOD.Scid mice - Culture of HEK and A431 
cells, generation of cell clones stably expressing 
GRK2, GRK2-K220R, RKIP, or the GRK2-
specific peptide inhibitor (21,22) was performed 
essentially as described (24). Cells were 
maintained in high-glucose DMEM with 10 % 
fetal bovine serum and 4 mM L-glutamine at 37 
°C, in a humidified atmosphere with 5 % CO2. 
The cell proliferation assay was performed 
essentially as detailed previously (3). As 
indicated, HEK cells were also cultured in 
growth factor-supplemented [50 ng/ml 
epidermal growth factor, (EGF)] DMEM and 
plated on mitomycin-inactivated mouse 
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embryonic fibroblasts (MEF) as feeder cells 
essentially as described (25). For in vivo cell 
expansion, NOD.Scid mice (age 3 months) 
received an injection of 6-8 x 106 cells/200 µl 
PBS (24). Two weeks (A431) or four weeks 
(HEK) after the injection, mice were 
anesthetized with ketamine/xylazine (100/10 
mg/kg), perfused intracardially with 
physiological phosphate buffer, pH 7.2, and 
expanded cell clones were rapidly isolated and 
processed for further use. In addition, cells were 
also isolated from NOD.Scid mouse-expanded 
clones and re-cultured in DMEM as detailed 
above. Animal experiments were performed in 
accordance with the NIH guidelines, and 
reviewed and approved by the local committee 
on animal care and use (University of Zurich). 
Immunohistology, immunoblotting, and 
protein techniques - Immunohistological 
detection of phospho-ERK1/2 was performed 
with phospho-ERK1/2-specific antibodies 
(phosphorylated at Thr202/Tyr204 of ERK1, and 
Thr185/Tyr187 of ERK2; E10 mouse mAb, Cell 
signalling), and GRK2 was detected with 
GRK2-specific antibodies (raised in rabbit 
against full-length recombinant GRK2 protein) 
on cryosections of NOD.Scid mouse-expanded 
HEK and A431 clones, respectively, similarly as 
described (24,26). For detection of phospho-
ERK1/2 in hearts of transgenic mice, we used 
paraffin-embedded sections. Nuclear 
fragmentation as a marker of apoptosis was 
determined in situ by TdT-mediated dUTP-
biotin nick end labeling (TUNEL) technology 
(Roche Diagnostics, Germany) with paraffin-
embedded sections prepared from transgenic 
hearts as detailed previously (26,27). The 
TUNEL technology was also used to determine 
the nuclear fragmentation of neonatal mouse 
cardiomyocytes, which were isolated from B6 
mice, Tg-RKIP and Tg-GRK-Inh mice 1-3 days 
after birth essentially as described (9). All 
sections/cells were imaged with a Leica 
DMI6000 microscope equipped with a DFC420 
camera. Immunoblotting was used to determine 
the protein level of GRK2, GRK2-K220R, 
ERK1 (MAPK3), ERK2 (MAPK1), and 
phospho-ERK1/2 in cells, NOD.Scid mouse-
expanded clones and organ tissue from 
transgenic mice as described (24,26). We also 
used standard immunoblotting and 
immunohistology techniques (9,27,28) applying 
RKIP-specific antibodies (affinity-purified 
polyclonal antibodies raised in rabbit against 
full-length recombinant RKIP protein) to detect 
the over-expressed RKIP protein in RKIP-
transgenic hearts. Co-enrichment of Raf1 and 
GRK2 with RKIP was performed similarly as 
described (9). The GRK2-specific peptide 
inhibitor (GRK-Inh) was detected in 
immunoblot after Tricine-SDS-PAGE with anti-
GRK-Inh antibodies (affinity-purified polyclonal 
antibodies raised in rabbit against the KLH-
coupled GRK-Inh peptide). Nuclear phospho-
ERK1/2 levels were quantified with the nuclear 
fraction of NOD.Scid mouse-expanded HEK and 
A431 clones, and organ tissue of transgenic and 
non-transgenic mice. The nuclear fraction was 
adjusted to a protein concentration of 0.2 µg/µl, 
solubilized by buffer (500 mM NaCl, 1 mM 
EDTA, 1 % Triton X100, 1 % SDS, 50 mM Tris 
pH 7.4) supplemented with protease/phosphatase 
inhibitors and assayed for phospho-ERK1/2 by 
immunoblotting, or a sandwich ELISA 
according to the instructions of the manufacturer 
(Pierce). Nuclear samples were normalized to 
histone H2B. 
For subcellular fractionation, dispersed 
NOD.Scid mouse-expanded clones or mouse 
organ tissue were suspended in ice-cold buffer 
containing 0.25 M sucrose, 20 mM HEPES, pH 
7.4, 10 mM KCl, 2 mM MgCl2, 1 mM DTT, 
supplemented with protease/phosphatase 
inhibitors, and homogenized on ice with a 
dounce homogenizer. After centrifugation for 10 
min at 4 °C (750 x g), the nuclear pellet was 
washed twice with ice-cold buffer, and stored as 
the nuclear fraction at -80°C. The purity of the 
nuclear fraction was controlled by immunoblot 
detection of histone H2B and the absence of 
cytosolic proteins.  
NanoLC-ESI-MS/MS – To enrich 
proteins interacting with the GRK2-specific 
peptide inhibitor, GRK-Inh-expressing tumors 
were pulverized under liquid nitrogen. After 
solubilization for 30 min at 4 °C with 
solubilization buffer (1 % sodium deoxycholate, 
0.05 % SDS, 0.05 % Tween-20 in PBS, pH 7.4, 
supplemented with protease inhibitors), 
insoluble material was removed by 
centrifugation. The supernatant was diluted 1:5 
in PBS (supplemented with protease inhibitors) 
and subjected to affinity chromatography with 
anti-GRK-Inh-antibodies (6 mg affinity-purified 
IgG/ml Affigel 10). After overnight incubation 
at 4 °C, unbound proteins were removed by 
extensive washing with PBS (20 column 
volumes), and bound proteins were eluted with 
0.25 M NH4OH/10% dioxane (pH 11). The pH 
was immediately adjusted to pH 7.4, eluted 
proteins were concentrated by acetone 
precipitation, dissolved by 8M urea and 
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subjected to 8 % urea-containing SDS-PAGE 
under reducing conditions. After coomassie 
brilliant blue staining, the GRK2-reactive band 
was cut and subjected to nanoLC-ESI-MS/MS. 
Protein identification using nanoLC-ESI-
MS/MS was performed by Proteome Factory 
(Proteome Factory AG, Berlin, Germany). The 
MS system consisted of an Agilent 1100 
nanoLC system (Agilent, Boeblingen, 
Germany), PicoTip emitter (New Objective, 
Woburn, USA) and an Esquire 3000 plus ion 
trap MS (Bruker, Bremen, Germany). The cut 
protein band was in-gel digested by trypsin 
(Promega, Mannheim, Germany) and applied to 
nanoLC-ESI-MS/MS. After trapping and 
desalting the peptides on enrichment column 
(Zorbax SB C18, 0.3 x 5 mm, Agilent) using 1 
% acetonitrile/0.5 % formic acid solution for 
five minutes, peptides were separated on Zorbax 
300 SB C18, 75 µm x 150 mm column (Agilent) 
using an acetonitrile/0.1 % formic acid gradient 
from 5 % to 40 % acetonitrile within 40 min. 
MS spectra were automatically taken by Esquire 
3000 plus according to the manufacturer`s  
instrument settings for nanoLC-ESI-MS/MS 
analyses. Proteins were identified using MS/MS 
ion search of Mascot search engine (Matrix 
Science, London, England) and nr protein 
database (National Center for Biotechnology 
Information, Bethesda, USA). Ion charge in 
search parameters for ions from ESI-MS/MS 
data acquisition were set to “1+, 2+ or 3+” 
according to the instrument`s and method`s 
common charge state distribution. 
Transthoracic echocardiography -
Transthoracic echocardiography was performed 
with a Vivid 7 echocardiograph system (GE 
Healthcare) and a 12 MHz linear array 
transducer similarly as described (27,29). 
Transthoracic echocardiography was used to 
characterize the cardiac function of transgenic 
and non-transgenic B6 and FVB mice without 
and with 4 weeks of chronic pressure overload 
imposed by abdominal aortic constriction, AAC, 
performed as detailed previously (27). 
Microarray gene expression profiling - 
Whole genome microarray gene expression 
profiling of cells, NOD.Scid mouse-expanded 
clones and heart tissue of RKIP-transgenic, 
GRK-Inh-transgenic and B6 mice was 
performed as described (24,30). We used 
GeneChip Human genome U133 Plus 2.0 Arrays 
for human cells and Mouse genome MG430 2.0 
Arrays for mouse cardiac tissue (Affymetrix). 
Gene ontology (GO) analyses of microarrray 
data were performed with GCOS/RMA 
processed data using GeneSpring GX software 
(Agilent). Data were compared between groups 
using the unpaired two-tailed Student`s t test. P 
values of <0.05 were considered significant 
unless specified otherwise. All microarray gene 
expression data were deposited to the NCBI 
GEO database (accession numbers GSE42753 
and GSE42771).  
Selected gene expression data were 
confirmed by real-time qRT-PCR using a 
LightCycler 480 (Roche). Sequences of the 
forward and reverse primers of genes studied 
were as follows: FOS forward, 5`-
CATAGCATTAACTAATCTATTGGGTTCA-
3; FOS reverse, 5`-
CACACTATTGCCAGGAACACAGTAGT-3`; 
PEBP1 (RKIP) forward, 5`-
GGAGACCACCGTGGCAAATTCAAG-3`; 
PEBP1 (RKIP) reverse, 5`-
GCTGCTCGTACAGTTTGGGCACAT-3`; FN 
forward 5-
ATGTTAGCAGACCCAGCTTAGAGTTC-3`; 
FN reverse 5`-
TCAGGAAACTCCCAGGGTGATGCTTG-3`; 
GRK-Inh forward 5`-
CATGGCCAAGTTCGAGC-3`; GRK-Inh 
reverse 5`-GTCACTCGCTGGTGATG-3`; Scd1 
forward, 5`-
GTTATAGACGGCAGTTGGCACTGG-3`; 
Scd1 reverse, 5`-
CTTAGCCCAGGAGTTTCTTGGGTT-3`; 
Fasn forward, 5`-
CCGACTCCCTTACGAGGCTGTGT-3`; Fasn 
reverse, 5`-
CTGCACAGCGCTCTATCCACTGA-3`; Ucp1 
forward, 5`-
CACTGCCAAAGTCCGCCTTCAGA-3`; Ucp1 
reverse, 5`-
GCAGGCAGACCGCTGTACAGTT-3`; Retn 
forward, 5`-
GTCCTGCTAAGTCCTCTGCCAC-3`; Retn 
reverse, 5`-
GGCTGCTGTCCAGTCTATCCTTG-3`. 
Confocal FRET imaging - The GRK2-
mediated interaction of enhanced yellow 
fluorescent protein (EYFP)-tagged β-arrestin1 
with B2R-Cerulean in transfected HEK cell 
clones without (control) or with expression of 
GRK2 or the dominant-negative GRK2-K220R, 
respectively, was determined in the absence or 
presence of bradykinin (1 µM, 8 min) and 
quantified by confocal FRET imaging and 
acceptor photobleaching with a confocal laser-
scanning microscope (SP5-CLSM, Leica) 
similarly as described (21).  
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Plasmids - For transfection of HEK and 
A431 cells, we used the eukaryotic expression 
plasmid pcDNA3.1 (Invitrogen) and inserted the 
following cDNAs: ARRB1-EYFP (EYFP fused 
in-frame with the C-terminal amino acid codon 
of ARRB1); B2R-Cerulean (21), (Cerulean fused 
with a linker encoding GlyGlyGlyGlyGly in-
frame with the codon for the C-terminal amino 
acid 391 of BDKRB2); RKIP [cDNA encoding 
PEBP1 (28)]; GRK2 (cDNA encoding 
ADRBK1); GRK2-K220R (cDNA encoding 
ADRBK1 with point mutation exchanging lysine 
220 for arginine); GRK-Inh [DNA encoding the 
sequence MAKFERLQTVTNYFITSE (21), a 
GRK2-specific peptide inhibitor (21,22)]. 
Expression of GRK2 was down regulated by 
RNA interference (RNAi) by POL II driven 
expression of a GRK2-targeting miR. The 
following hairpin-forming oligonucleotides were 
hybridized to form a 60-bp duplex and inserted 
into pcDNA6.2-GW(miR) (Invitrogen): 5`-
TGCTGATAGAATTCCACCAAGGGCCTGTT
TTGGCCACTGACTGACAGGCCCTTTGGA
ATTCTAT-3`, 5`-
CCTGATAGAATTCCAAAGGGCCTGTCAG
TCAGTGGCCAAAACAGGCCCTTGGTGGA
ATTCTATC-3`. 
Statistics - Results are presented as mean 
± s. d. unless indicated otherwise. Unpaired two-
tailed Student`s t-test was used to calculate P 
values. Analysis of variance was performed with 
Prism (GraphPad). Statistical significance was 
set at a P value of < 0.05. 
 
RESULTS 
Dominant-negative activity of the 
kinase-deficient GRK2-K220R mutant in HEK 
cells- To analyze the impact of GRK2 and 
GRK2 inhibition on cell growth, we used the 
kinase-deficient GRK2-K220R, which is 
reported to act as a dominant-negative mutant 
(31). We generated HEK cell clones stably 
expressing GRK2 or the kinase-deficient GRK2-
K220R (Fig. 1A). Protein levels were similar 
because GRK2 and GRK2-K220R exerted 
comparable kinase-independent functions such 
as inhibition of a Gαq/11-mediated calcium 
signal stimulated by the bradykinin B2 receptor, 
B2R (Fig. 1B). To confirm kinase activity of 
GRK2, we expressed a GRK2-specific peptide 
inhibitor (21,22), and determined its effect on 
GRK2-mediated desensitization of the calcium 
signal stimulated by B2R, which is a kinase 
substrate of GRK2 (32). In agreement with 
kinase inhibition, GRK2-mediated 
desensitization of the B2R-stimulated calcium 
signal was partially reversed by expression of 
the GRK2-specific peptide inhibitor whereas the 
kinase inhibitor did not affect the kinase-inactive 
GRK2-K220R (Fig. 1B). 
We next analyzed whether GRK2-
K220R exerted dominant-negative activity in 
HEK cells and inhibited the endogenously 
expressed GRK2 (Fig. 2A). As a kinase effect of 
GRK2, we determined the GRK2-triggered 
interaction of Cerulean-tagged B2R with β-
arrestin1-EYFP by fluorescence resonance 
energy transfer (FRET) measurement. Confocal 
FRET imaging revealed that the kinase-deficient 
GRK2-K220R completely prevented the 
bradykinin-stimulated interaction of B2R-
Cerulean with β-arrestin1-EYFP indicating 
dominant-negative activity (Fig. 2B, C). As a 
control, the expression of GRK2 did not 
decrease the bradykinin-enhanced FRET 
intensity of the B2R-Cerulean interaction with 
β-arrestin1-EYFP (Fig. 2B, C) 
Dominant-negative GRK2-K220R 
enhanced the growth of NOD.Scid mouse-
expanded HEK clones- We determined whether 
GRK2 or the dominant-negative GRK2-K220R 
affected the proliferation of HEK cells. In 
agreement with previous results (3), neither 
GRK2 nor GRK2-K220R affected the 
proliferation rate of cultured HEK cells (Fig. 
3A). 
As GRK2-dependent growth control is 
active in vivo (2-4), we performed cell expansion 
in immunodeficient NOD.Scid mice because the 
xenograft transplantation model had previously 
been used to overcome limitations of cell culture 
(24). In contrast to cultured cells, GRK2 
inhibition by the dominant-negative GRK2-
K220R led to a strongly increased growth rate in 
vivo upon cell expansion in NOD.Scid mice 
whereas GRK2-expressing clones showed a 
reduced cell mass (Fig. 3B). As a control, 
immunoblotting and immunohistology 
demonstrated comparable protein levels of 
GRK2-K220R and GRK2, respectively (Fig. 3C, 
D). 
We searched for the mechanism 
underlying the growth control by GRK2. The 
mitogen-activated protein kinase (MAPK) 
pathway triggered by RAS-dependent activation 
of RAF and MEK is a universal signal 
transduction cascade involved in cell survival, 
growth, and proliferation (33,34). Because 
MAPK pathway activation is also a common 
feature of many GRK2 receptor-substrates (35), 
we analyzed the activation of the MAPK, 
ERK1/2, of in vivo-expanded HEK clones. The 
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GRK2-K220R-induced increase in HEK cell 
mass correlated with a high level of activated 
phospho-ERK1/2 (Fig. 3E). Vice versa, the 
reduced growth of GRK2-expressing clones was 
accompanied by decreased ERK1/2 
phosphorylation (Fig. 3E). 
Up-regulation of MAPK pathway genes 
in NOD.Scid mouse-expanded HEK clones 
expressing GRK2-K220R- To decipher the basis 
of the differential growth regulation of cultured 
cells and NOD.Scid mouse-expanded clones, we 
performed microarray gene expression profiling. 
In agreement with sustained ERK1/2 activation 
(cf. Fig. 3E), microarray gene expression 
analysis showed that MAPK pathway target 
genes such as FOS were specifically increased in 
NOD.Scid mouse-expanded clones expressing 
dominant-negative GRK2-K220R compared to 
GRK2-expressing clones (Fig. 4 and Fig. 5A - 
left panel). In contrast to the NOD.Scid model, 
expression of MAPK target genes was low in 
cultured HEK cells and not different between 
GRK2- and GRK2-K220R-expressing cells, 
respectively (Fig. 4 and Fig. 5A - middle panel). 
NOD.Scid mice did not irreversibly modify the 
MAPK pathway because MAPK target gene 
induction disappeared when cells were “re-
cultured” in vitro after in vivo expansion (Fig. 4 
and Fig. 5A - right panel). As a control, a typical 
kinase-mediated effect of GRK2, i.e. inhibition 
of fibronectin (FN) expression depending on 
TGFβ (36) as a stimulus which is active in vitro 
and in vivo, was similarly detected in HEK 
clones expanded in vivo or cultured in vitro (Fig. 
4 and Fig. 5A). Taken together, in vivo cell 
expansion in NOD.Scid mice revealed GRK2-
dependent regulation of the MAPK pathway. 
Real-time quantitative reverse 
transcription PCR (real-time qRT-PCR) 
confirmed substantial FOS expression after 
NOD.Scid mouse expansion while FOS was low 
in cultured cells (Fig. 5B). Real-time qRT-PCR 
also confirmed that GRK2-K220R up-regulated 
FOS in NOD.Scid mouse-expanded HEK clones 
compared to clones expressing GRK2 (Fig. 5B, 
left panel). In contrast to in vivo cell expansion, 
GRK2 and GRK2-K220R did not affect the 
expression of FOS in cultured HEK cells, either 
before or after in vivo expansion in NOD.Scid 
mice (Fig. 5B, middle and right panel). These 
experiments further support that in vivo cell 
expansion in NOD.Scid mice was essential to 
manifest MAPK target gene modulation by 
GRK2 and GRK2-K220R, respectively.  
 Dominant-negative GRK2-K220R of 
NOD.Scid mouse-expanded HEK clones 
enhanced MAPK activation and nuclear 
translocation - The high expression of the 
nuclear MAPK target, FOS, pointed to sustained 
activation and nuclear translocation of the MAP-
kinases, ERK1/2 (34) upon GRK2 inhibition by 
GRK2-K220R. In agreement with that notion, 
immunohistology analysis with phospho-
ERK1/2-specific antibodies revealed an 
increased total phospho-ERK1/2 level with a 
substantial amount of phospho-ERK1/2 in the 
nuclei of a NOD.Scid mouse-expanded GRK2-
K220R-expressing HEK clone compared to the 
control or GRK2-expressing clone (Fig. 5C). 
Quantitative immunoblot evaluation confirmed 
those data and showed a high level of activated 
phospho-ERK1/2 in the nuclear fraction of 
GRK2-K220R-expressing clones whereas 
nuclear phospho-ERK1/2 was low in GRK2-
expressing clones (Fig. 5D). 
Similarly as in cultured HEK cells (cf. 
Fig. 2), kinase-inactivated GRK2-K220R of 
NOD.Scid mouse-expanded HEK clones could 
act as a dominant-negative protein, which 
prevented signal desensitization by scavenging 
the cellular β-arrestin pool whereas GRK2 was 
released from β-arrestin as determined by co-
immunoenrichment (Fig. 5E). Together these 
findings suggest that dominant-negative GRK2-
K220R could enhance receptor-stimulated 
(MAPK) signaling by preventing β-arrestin-
dependent signal desensitization.  
Trophic effects of MEF feeder cells 
reconstituted GRK2-dependent growth control in 
vitro - To reconstitute the trophic effect of 
NOD.Scid mice on HEK growth in vitro, growth 
factor-supplemented HEK cells were plated on 
mouse embryonic fibroblasts (MEFs) as feeder 
cells (25). Culture of HEK cells with MEF 
feeder cells revealed a GRK2-mediated 
reduction of HEK cell proliferation whereas 
dominant-negative GRK2-K220R promoted cell 
proliferation (Fig. 6A). The MEK inhibitor 
PD0325901 prevented the GRK2-mediated 
growth regulation indicating dependence on the 
MAPK pathway (Fig. 6A). In agreement with 
involvement of the MAPK pathway, cell 
proliferation control by GRK2 correlated with 
regulation of the nuclear phospho-ERK1/2 level 
(Fig. 6B). Similarly as in NOD.Scid mouse-
expanded clones, GRK2 reduced the nuclear 
phospho-ERK1/2 level while GRK2 inhibition 
by GRK2-K220R significantly increased the 
amount of nuclear phospho-ERK1/2 of HEK 
cells plated on MEF feeder cells (Fig. 6B). 
These experiments strongly suggest that the 
apparent difference between in vivo and in vitro 
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experiments could be due to the lack of 
sustained MAPK-activating growth-promoting 
stimuli under standard cell culture conditions. 
 The RAF-MAPK axis triggered by GRK2 
inhibition promotes tumor growth- Sustained 
MAPK pathway activation induces and/or 
promotes growth of malignant tumors such as 
squamous-cell carcinoma (37). Therefore we 
used squamous cell carcinoma A431 cells, to 
analyze whether the GRK2-K220R-dependent 
enhancement of the MAPK pathway affected 
tumor growth. A431 clones with comparable 
protein levels of GRK2 and GRK2-K220R, 
respectively, were used (Fig. 7A, left panel). 
Analogous to NOD.Scid mouse-expanded HEK 
clones, immuno-techniques revealed a high 
protein level of activated phospho-ERK1/2 in 
the nuclei of NOD.Scid-expanded A431 tumors 
expressing dominant-negative GRK2-K220R 
whereas phospho-ERK-1/2 was low in GRK2-
expressing tumors (Fig. 7B,C). In agreement 
with growth-promoting MAPK activation, 
expression of the MAPK target, FOS, was 
induced in GRK2-K220R-expressing tumors 
(Fig. 7D), and A431 tumor mass increased (Fig. 
7E). 
To further investigate whether GRK2 
inhibition triggered the growth-promoting 
MAPK pathway, we used a GRK2-specific 
peptide inhibitor (cf. Fig. 1B and ref. 21,22). 
Expression of the GRK2-specific peptide 
inhibitor (Fig. 7A, right panel) significantly 
increased the level of activated phospho-ERK1/2 
(Fig. 7B,C), and induced the nuclear MAPK 
target FOS similarly as did GRK2-K220R (Fig. 
7D, panel 3 vs. 2). Concomitantly, tumor growth 
was enhanced (Fig. 7F). Thus, GRK2 inhibition 
either by a dominant-negative mutant or a 
peptide inhibitor activated the growth-promoting 
MAPK pathway, induced the expression of the 
MAPK target, FOS and enhanced tumor growth. 
 The MAPK pathway is triggered by the 
proto-oncogene RAF. To analyze the 
involvement of RAF, we applied the RAF kinase 
inhibitor protein, RKIP (Fig. 7G), which is a 
dual-specific GRK2 and RAF-MAPK inhibitor 
(9,28,38). In contrast to sole GRK2 inhibition, 
RKIP prevented the increase in nuclear phospho-
ERK1/2 (Fig. 7B,C), and FOS was not induced 
in A431 clones expressing RKIP (Fig. 7D, panel 
4 vs. 1-3). Concomitantly, GRK2 inhibition by 
RKIP did not enhance tumor growth (Fig. 7F). 
As a control, the expressed RKIP protein level 
was sufficient to scavenge the cellular RAF1 and 
GRK2 protein pools as assessed by co-
immunoenrichment (Fig. 7H), confirming dual-
specific GRK2 and RAF1 inhibition by RKIP 
(9,28,38). 
In agreement with the requirement of the 
RAF/MEK/ERK pathway for enhanced tumor 
growth upon GRK2 inhibition, the MEK 
inhibitor PD0325901 significantly reduced the 
tumor mass of GRK2-inhibitor-expressing A431 
tumors whereas the mass of RKIP-expressing 
A431 tumors was not affected (Fig. 7I). 
Moreover, MAPK activation induced by the 
GRK2-specific inhibitor was dependent on 
GRK2 because the GRK2-specific peptide 
inhibitor did not significantly increase the 
nuclear phospho-ERK1/2 level upon down-
regulation of GRK2 by RNA interference (Fig. 
7K). As an indicator for comparable GRK2 
inhibition, the target gene FN (cf. Fig. 5A) was 
similarly up-regulated by the three different 
GRK2 inhibitors whereas wild-type GRK2 
reduced the expression of FN (Fig. 7L). 
Together the experiments strongly suggest that 
the RAF-MAPK axis triggered by GRK2 
inhibition promoted the growth of malignant 
A431 tumors. 
Enrichment of GRK2 by GRK-Inh-
specific immuno-affinity chromatography and 
identification by nano-LC-ESI-MS/MS – To 
analyze the interaction of the GRK2-specific 
peptide inhibitor (GRK-Inh) with GRK2 in vivo, 
we performed affinity chromatography with 
GRK-Inh-reactive antibodies. Proteins were 
immuno-affinity enriched from GRK-Inh-
expressing tumor tissue and separated by SDS-
PAGE. Silver staining of enriched proteins 
revealed a predominant protein band with an 
apparent molecular weight of 79 ± 3 kDa, which 
was not enriched by the control column (Fig. 
8A). Immunoblotting demonstrated that the 
enriched protein co-migrated with the GRK2-
immunoreactive protein band (Fig. 8A). The 
protein band was excised from the gel, and 
subjected to identification by nano-LC-ESI-
MS/MS. With 27 matching peptides, the Mascot 
search engine identified the human beta-
adrenergic receptor kinase 1 (GRK2) with the 
highest probability score (Fig. 8B and 
Supplemental data). Regions of identified 
peptides matching with the human GRK2 
protein sequence are shown (Fig. 8B). Together 
these experiments provide strong evidence that 
the GRK2-specific peptide inhibitor interacts 
with the GRK2 protein in vivo. 
MAPK pathway activation in transgenic 
mice with systemic expression of the GRK2-
specific peptide inhibitor – To investigate 
whether GRK2 inhibition by the GRK2-specific 
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peptide inhibitor also regulated the MAPK 
pathway in non-tumor tissue, we generated 
transgenic mice expressing the GRK2-specific 
peptide inhibitor under control of the CMV 
immediate–early promoter/enhancer, which 
directs ubiquitous expression in transgenic mice 
(39). Two different transgenic mouse lines were 
identified, which showed high and low level, 
respectively, of the GRK2-specific peptide 
inhibitor, in different organs, i.e. kidney, lung, 
thymus and heart (Fig. 9A). 
Organs with transgenic expression of the 
GRK2-specific peptide inhibitor also displayed 
an increased Fos protein level compared to non-
transgenic B6 controls, suggesting enhanced 
activation of the MAPK pathway upon GRK2-
specific peptide inhibitor expression (Fig. 9B). 
In agreement with MAPK activation, nuclear 
and cytosolic protein levels of activated 
phospho-ERK1/2 were significantly higher in 
organs with GRK2-specific peptide inhibitor 
expression compared to B6 control tissue while 
total cytosolic ERK1/2 protein was not different 
(Fig. 9C,D). These experiments show that the 
GRK2-specific peptide inhibitor promoted 
activation of the MAPK pathway and Fos 
induction in vivo, not only in xenografted tumor 
tissue, but also in different organs of transgenic 
mice. 
Kinase-inhibited GRK2 stabilized 
activated phospho-ERK1/2 in vivo – We 
analyzed the interaction of GRK2 with activated 
phospho-ERK1/2. Co-enrichment studies 
revealed that kinase-inhibited GRK2 (inhibited 
by the GRK2-specific peptide inhibitor) or 
kinase-deficient GRK2-K220R showed an 
increased interaction with activated phospho-
ERK1/2 compared to kinase-active GRK2 of 
A431 tumor tissue (Fig. 9E, left and right panel). 
The increased interaction of kinase-inhibited 
GRK2 with phospho-ERK1/2 was also detected 
in different organs of mice with transgenic 
expression of the GRK2-specific peptide 
inhibitor (Fig. 9F). These findings suggest that 
kinase-inhibited GRK2 stabilized phospho-
ERK1/2. The phospho-ERK1/2-stabilizing 
activity of kinase-inhibited GRK2 could 
contribute to sustained phospho-ERK1/2 
activation required for MAPK target gene 
induction of A431 tumors and organs from 
transgenic mice. 
GRK2-inhibition by transgenic RKIP or 
GRK-Inh expression in hearts of transgenic 
mice- Enhanced activation of the MAPK 
pathway can exert cardioprotection (16). 
Because heart tissue from transgenic mice with 
GRK2-specific peptide inhibitor expression 
under control of the CMV promoter showed 
increased MAPK pathway activation (cf. Fig. 9), 
we investigated the cardiac profile of the GRK2-
specific peptide inhibitor relative to RKIP, 
which is a dual-specific GRK2 and RAF/MAPK 
inhibitor. To this end mice with myocardium-
specific expression of RKIP or the GRK2-
specific peptide inhibitor, respectively, were 
generated (Fig. 10A). Hearts of transgenic 
founder lines (two different lines for each 
transgene) showed increased levels of the RKIP 
protein and the GRK2-specific peptide inhibitor, 
respectively (Fig. 10B). GRK2 inhibition was 
effective in both models as evidenced by 
microarray gene expression profiling: more than 
60 % of regulated probe sets of RKIP-transgenic 
hearts showed concordant regulation with hearts 
expressing the GRK2-specific peptide inhibitor 
(Fig. 10C, left panel, and Fig. 11). Moreover, the 
extent of gene regulation was comparable 
between RKIP-transgenic and GRK-Inh-
transgenic hearts (Fig. 11). These in vivo 
observations are compatible with equivalent in 
vitro potencies of RKIP and GRK-Inh in 
inhibiting GRK2 (9,22). 
The GRK2-specific peptide inhibitor 
enhanced whereas RKIP inhibited the MAPK 
pathway in vivo - Only 3 probe sets were up-
regulated by the GRK2-specific peptide inhibitor 
and down regulated by RKIP, i.e. the MAPK 
target genes Fos, Egr-1, and Ctgf (Fig. 10C, 
right panel). Altered Fos expression was 
confirmed by immunoblotting, which showed 
increased cardiac Fos protein in transgenic 
hearts expressing the GRK2-specific peptide 
inhibitor whereas RKIP decreased Fos (Fig. 
10D). The induction of Fos correlated with 
increased MAPK activation as demonstrated by 
increased (nuclear) phospho-ERK1/2 levels in 
transgenic hearts expressing the GRK2-specific 
peptide inhibitor while phospho-ERK1/2 was 
reduced by RKIP (Fig. 10E-G). As a control, the 
protein level of over-expressed RKIP was 
sufficient to scavenge the entire cardiac GRK2 
and Raf1 pools (Fig. 10H). Together the 
experiments show that transgenic RKIP over-
expression induced Raf1-MAPK axis inhibition 
whereas the GRK2-specific peptide inhibitor 
enhanced the MAPK pathway. 
Inhibition of the MAPK pathway by 
transgenic RKIP over-expression triggered signs 
of heart failure in B6 mice- As the RAF-MAPK 
axis is essential for cardiomyocyte survival 
(16,17,40), cardiomyocyte death was assessed 
by TUNEL staining. There was a significant 
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increase in the number of TUNEL-positive 
nuclei in RKIP-transgenic hearts whereas signs 
of cardiomyocyte apoptosis were low in GRK2-
inhibitor-expressing hearts (Fig. 12A,C). 
In agreement with enhanced 
cardiomyocyte death, RKIP-transgenic B6 mice 
developed heart dilatation and cardiac 
dysfunction at advanced age as determined by 
transthoracic echocardiography and histology 
analysis, respectively (Fig. 12A,B). Cardiac 
dysfunction of RKIP-transgenic B6 mice was 
accompanied by cardiac lipid overload and up-
regulation of cardiac lipid metabolism genes 
(Fig. 12D,E), indicating the transition to heart 
failure (27). As a control, there was a trend 
towards improved cardiac function of GRK2-
specific peptide inhibitor-expressing B6 mice 
(Fig. 12A), confirming positive inotropy induced 
by GRK2 inhibition (7,10-15). Moreover, GRK-
Inh-transgenic hearts did not develop cardiac 
dilatation or cardiac lipid overload (Fig. 12B-E). 
Thus, GRK2 inhibition seemed to confer 
cardioprotection whereas dual inhibition of the 
GRK2 and Raf/MAPK axis by RKIP produced 
cardiotoxic side-effects. 
The cardiotoxic effect of RKIP was 
confirmed with neonatal cardiomyocytes 
isolated from RKIP-transgenic hearts (Fig. 12F). 
RKIP over-expression induced a 9-fold increase 
in TUNEL-positive cardiomyocytes compared to 
neonatal cardiomyocytes isolated from GRK-
Inh-transgenic mice (Fig. 12F). RKIP-dependent 
cardiomyocyte apoptosis was attributed to 
MAPK pathway inhibition, because a MEK 
inhibitor strongly increased cardiomyocyte death 
of B6 control cardiomyocytes but had no 
substantial effect on RKIP-transgenic 
cardiomyocytes (Fig. 12G).  
Inhibition of GRK2 in FVB mice by 
transgenic expression of RKIP or GRK-Inh- We 
asked whether the genetic background of B6 
mice was linked to the different phenotype of the 
two GRK2 inhibitors. Transgenic FVB mice 
with myocardium-specific RKIP expression 
were generated (Fig. 13A-C). Analogous to 
RKIP-transgenic B6 mice, the TUNEL assay 
revealed enhanced cardiomyocyte apoptosis of 
RKIP-transgenic FVB mice (Fig. 13A). 
Concomitantly, cardiac hypertrophy with 
dilatation and cardiac dysfunction developed in 
RKIP-transgenic FVB mice (Fig. 13A,B). Taken 
together these data show that dual inhibition of 
the GRK2-RAF/MAPK axis by RKIP could be 
cardiotoxic in B6 and FVB mice, independent of 
the genetic background of the mouse. 
 On the other hand, hearts of transgenic 
FVB mice expressing the GRK2-specific peptide 
inhibitor (Fig. 13D) were not dilated and showed 
a high left ventricular ejection fraction similarly 
as B6 mice with transgenic GRK-Inh expression 
(Fig. 13E,F vs. Fig. 12). In agreement with 
cardioprotective GRK2 inhibition (10-15), the 
GRK2-specific peptide inhibitor retarded the 
development of chronic pressure overload-
induced cardiac hypertrophy with dilatation and 
cardiac dysfunction imposed by 4 weeks of 
abdominal aortic constriction (Fig. 13E,F). Thus, 
the GRK2-specific peptide inhibitor had a 
comparable cardiac profile in FVB and B6 mice 
and was protective against pressure overload-
induced cardiac damage. 
 
DISCUSSION 
Our study revealed a previously 
unrecognized role of the desensitizing kinase, 
GRK2, in restraining the MAPK pathway. 
GRK2-mediated desensitization of MAPK-
activating GPCRs and non-GPCR substrates is 
well established (1,35,41). In addition, 
prevention of nuclear MAPK signaling could be 
mediated by the GRK2-dependent recruitment of 
β-arrestin, which retains MAPK in the cytosol 
(42-44). This mechanism is not only valid for 
GPCRs (42, 43) but also reduces nuclear 
translocation of ERK1/2 upon receptor tyrosine 
kinases co-stimulation such as the epidermal 
growth factor receptor (44). 
While GRK2 suppressed MAPK 
activation and nuclear translocation, GRK2 
inhibitors enhanced the MAPK pathway, 
induced nuclear ERK1/2 targets, notably the 
proto-oncogene FOS, and promoted tumor 
growth. Activation of the nuclear MAPK 
pathway upon GRK2 inhibition was not only 
observed in two different xenograft cell 
transplantation models but also occurred in vivo, 
in different organs of transgenic mice upon 
systemic GRK2 inhibition by transgenic 
expression of a GRK2-specific peptide inhibitor. 
Increased MAPK activation and target 
gene induction upon GRK2 inhibition could be 
due to β-arrestin scavenging/neutralization by 
kinase-inhibited GRK2. Thereby the formation 
of receptor/β-arrestin complexes is prevented as 
well as subsequent receptor/MAPK 
desensitization. In this respect, kinase-inhibited 
GRK2 acts as a dominant negative protein, 
which could differ from GRK2 knock-down 
because siGRK2 may trigger a shift to GRK5/6-
β-arrestin-mediated MAPK activation (45). 
Nevertheless, kinase-inhibited GRK2 and GRK2 
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down-regulation both enhance MAPK activity, 
and confer cardioprotection (10-15). In addition 
to β-arrestin neutralization, kinase-inhibited 
GRK2 could lead to sustained MAPK pathway 
activation essential for target gene induction 
(34), by stabilization of activated phospho-
ERK1/2, which was detected by co-enrichment 
studies in A431 tumor tissue and various organs 
of transgenic mice with systemic expression of 
the GRK2-specific peptide inhibitor.  
The tumor growth-promoting MAPK 
activity triggered by GRK2 inhibition 
overlapped with the cardioprotective activity of 
the MAPK cascade, which protects the 
myocardium against death-promoting stimuli 
(16,46). Notably, activation of ERK1/2 protects 
the heart against pressure overload-induced 
hypertrophic cardiomyopathy by stimulating 
cardiomyocyte survival and proliferation (46). 
Vice versa, genetic inhibition of ERK1/2 
enhanced cardiomyocyte apoptosis and 
predisposed to the development of pressure 
overload-induced heart failure (47). In 
agreement with those data, the pro-survival 
function of the MAPK cascade could contribute 
to the beneficial cardiac profile of GRK2 
inhibition because dual inhibition of the GRK2 
and RAF/MAPK axis by RKIP was detrimental 
and induced signs of heart failure in transgenic 
mouse lines with two different genetic 
backgrounds, most likely due to cardiotoxic 
RAF inhibition (17,40) and lack of 
cardioprotective MAPK activation (16,46,48). 
On the other hand, GRK2 inhibition 
without MAPK inhibition, by transgenic GRK2-
specific peptide inhibitor expression, was 
beneficial and retarded the development of 
chronic pressure overload-induced cardiac 
hypertrophy with dilatation and cardiac 
dysfunction. The cardioprotective activity of the 
GRK2-specific peptide inhibitor was comparable 
to the profile of GRK2 inhibition induced by the 
GRK2ct. Analogous to the GRK2-specific 
peptide inhibitor, transgenic expression of the 
GRK2ct also prevented the development of left 
ventricular dilatation and hypertrophy triggered 
by long-term chronic pressure overload  (49). 
Moreover, inhibition of GRK2 by the Gβγ-
scavenging GRK2ct, also preserved the activated 
MAPK pathway under aortic constriction (50).  
In addition to the cardio-protective 
MAPK pathway (48), GRK2 inhibition could 
enhance cardiomyocyte survival by increasing 
AKT-mediated induction of nitric oxide (51). 
Such a mechanism is active in vivo and 
contributes to cardio-protection of GRK2ct-
transgenic mice against acute myocardial 
ischemia/reperfusion injury (51). Since pro-
survival signaling by MAPK and AKT is 
integrated in the heart by specific scaffold 
proteins (52), future studies will have to 
determine the impact of the GRK2-specific 
peptide inhibitor on synergistic enhancement of 
MAPK- and AKT-mediated pro-survival 
pathways. 
While we found analogous results of the 
GRK2-specific peptide inhibitor and the 
dominant-negative GRK2-K220R mutant 
regarding MAPK activation and tumor cell 
proliferation, the cardiac phenotype of GRK2-
K220R still needs to be determined. Since 
GRK2-K220R is capable to inhibit GRK2 as a 
dominant-negative protein and by scavenging of 
Gβγ subunits similarly as does GRK2ct, GRK2-
K220R is also expected to exert 
cardioprotection.  
Taken together, our study investigated 
the in vivo profile of GRK2 inhibition by a 
GRK2-specific peptide inhibitor and the 
dominant-negative GRK2-K220R mutant. Our 
study provides strong evidence that GRK2 
inhibition induces activation of the growth-
promoting MAPK pathway in vivo, which seems 
critical for cardiomyocyte survival. In view of 
the well-established cell proliferation and cell 
growth-stimulating activity of the MAPK 
pathway, future efforts will have to balance the 
cardiomyocyte survival profile of GRK2 
inhibitors with the inherent risk of tumor cell 
growth. New approaches could focus on the 
development of dual-specific inhibitors, which 
stimulate GRK2-dependent cardiomyocyte 
survival but inhibit tumor cell proliferation.
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FIGURE LEGENDS 
 
FIGURE 1. Kinase-dependent and kinase-independent activity of GRK2 in cultured HEK cells. A. 
Immunoblot detection of HA-GRK2 in cultured HEK control cells (Cont., lane 1), and cells 
expressing HA-GRK2 (GRK2, lane 2) or HA-GRK2-K220R (K220R, lane 3). The lower panel is a 
control immunoblot detecting β-actin. B. Expression of comparable levels of a GRK2-specific kinase 
inhibitor (GRK-Inh; MAKFERLQTVTNYFITSE) partially reversed the GRK2-mediated 
desensitization of a bradykinin B2R-stimulated calcium signal in GRK2-expressing cells (left panel) 
whereas GRK2-K220R-expressing cells were not affected (right panel). Bars represent mean (± 
s.e.m., n=5). 
 
FIGURE 2. GRK2-K220R acts as a dominant-negative mutant in HEK cells. A. Immunoblot 
detection (IB: anti-GRK2) of the endogenously expressed GRK2 protein of HEK cells transfected 
with siRNA control plasmid (siCont., lane 1) or siGRK2 plasmid targeting GRK2 by RNA 
interference (siGRK2, lane 2). The loading control detected β-actin (lower panel). B, C. GRK2-
K220R inhibited the GRK2-mediated interaction of bradykinin-stimulated B2R-Cerulean with β-
arrestin1-EYFP. The interaction of B2R-Cerulean with β-arrestin1-EYFP was determined by confocal 
FRET imaging in the absence or presence of bradykinin (±Bk, 1 µM, 8 min) with control HEK cells 
[(B) left panel], and HEK cells expressing GRK2-K220R [(B), middle panel; (C) upper panels] or 
GRK2 [(B) right panel; (C) lower panels]. FRET efficiency was determined by acceptor photo-
bleaching. Data represent mean ± s.e.m. [(B) left panel: n=3; middle, right panel: n=9); bar: 10 µm.  
 
FIGURE 3. Dominant-negative GRK2-K220R enhanced the growth of NOD.Scid mouse-expanded 
HEK clones. A. Cell proliferation of in vitro cultured control HEK cells (Cont.), and HEK cells 
expressing GRK2 (GRK2) or GRK2-K220R (K220R). The left panel presents cell counts of day 4, 
and the right panel shows growth curves. Data represent mean (±s.d.) of three independent 
experiments performed in triplicates. B. Left panel: Mass of HEK clones after expansion in NOD.Scid 
mice (± s.d., n=5). The right panel shows a representative experiment (bar: 5 mm). C. Immunoblot 
detection of GRK2 (IB: anti-GRK2) in lysates of the indicated NOD.Scid mouse-expanded HEK 
clones (upper panel). The lower panel shows a control blot detecting β-actin. D. Immunohistological 
detection of GRK2 with GRK2-specific antibodies (anti-GRK2) in sections of a NOD.Scid mouse-
expanded control HEK clone (Cont.), and HEK clones with over-expression of GRK2 (GRK2) or 
GRK2-K220R (K220R), respectively. The preabsorption control is a GRK2-K220R-expressing clone. 
Cell nuclei were stained with hematoxylin (HE), bar: 50 µm. E. Immunoblot detection (IB) of 
phospho-ERK1/2 in total cell lysates of NOD.Scid mouse-expanded HEK clones (as indicated) with 
phospho-ERK1/2-specific antibodies. The left panel shows a representative immunoblot and the 
middle panel presents quantitative immunoblot evaluation by densitometric scanning of three 
different experiments. Bars represent mean (± s.d., n=3). Right panel: Total ERK1/2 protein levels 
were comparable between control, GRK2- and GRK2-K220R-expressing clones, respectively, as 
determined by immunoblotting (IB: anti-ERK1/2). All results are representative of 2-3 different HEK 
cell clones each. 
 
FIGURE 4. Microarray gene expression profiling revealed up-regulation of MAPK pathway genes in 
NOD.Scid mouse-expanded HEK clones expressing GRK2-K220R. Microarray gene expression 
profiling was performed with HEK clones expanded in vivo in NOD.Scid mice (Scid; left panels), of 
the respective in vitro-cultured HEK cell clones (HEK; middle panels), and of re-cultured cells after 
NOD.Scid mouse expansion (Ex-Scid; right panels). Gene expression data from GRK2-expressing 
(GRK-1, GRK-2) and GRK2-K220R-expressing HEK clones (K220R-1, K220R-2) are shown. 
Microarray probe sets were selected according to the following criteria: (i) significant difference 
(P≤0.01) between NOD.Scid mouse-expanded clones expressing GRK2-K220R (Scid-K220R-1; 
Scid-K220R-2) and GRK2 (Scid-GRK-1; Scid-GRK-2), (ii) >1.6-fold up-regulation in GRK2-
K220R-expressing clones relative to GRK2-expressing clones, and (iii) involvement in the MAPK 
pathway according to GO analysis. Probe sets with significant difference (K220R- relative to GRK2-
expressing HEK cells/clones) are marked in bold. The following genes were identified: FOS, v-fos 
FBJ murine osteosarcoma viral oncogene homolog; KLF2, Kruppel-like factor 2; S100A6, S100 
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calcium-binding protein A6, calcyclin; TRIB1, tribbles homolog 1; DCBLD2, discoidin, CUB and 
LCCL domain containing 2; CRYAB, crystallin, alpha B; PDGFB, platelet-derived growth factor beta 
polypeptide; EGR1, early growth response 1; DUSP1, dual specificity phosphatase-1. Signal 
intensities of probe sets detecting the TGFβ target fibronectin (FN) were significantly lower in all 
GRK2-expressing HEK cells/clones indicative of TGFβ-antagonistic activity of GRK2. Selected data 
of two gene chips are presented for each group (two different clones/cell preparations per gene chip). 
The probe set detecting GAPDH is shown as a control. 
 
FIGURE 5. Dominant-negative GRK2-K220R triggered the nuclear MAPK pathway of NOD.Scid 
mouse-expanded HEK clones. A. Microarray gene expression data of HEK clones after in vivo 
expansion in NOD.Scid mice (left panel), of cultured HEK cells (middle panel), and of re-cultured 
cells after NOD.Scid mouse expansion (right panel) are presented as heat map centered around the 
median value. Data filtering applied the following criteria: (i) significant difference (*P≤0.01) 
between NOD.Scid mouse-expanded HEK clones expressing GRK2-K220R and GRK2, (ii) >1.6-fold 
up-regulation in GRK2-K220R-expressing clones relative to GRK2-expressing clones, and (iii) 
involvement in the MAPK pathway according to GO analysis. Signal intensities of probe sets 
detecting the TGFβ target fibronectin (FN) were significantly lower in all GRK2-expressing HEK 
clones/cells reflecting intact TGFβ-antagonistic activity of GRK2. The probe set of GAPDH is shown 
as control. B. Left panel: real-time qRT-PCR showed up-regulated FOS expression of GRK2-K220R-
expressing HEK clones expanded in NOD.Scid mice.  Middle, right panels: real-time qRT-PCR 
analysis revealed low FOS expression of cultured HEK cells (middle panel) and of cells re-cultured 
after in vivo expansion in NOD.Scid mice (left panel). Expression data were normalized to β-actin 
(FOS/actin) and represent mean ± s.d., n=3. C. Detection of phospho-ERK1/2 by immunohistology 
with phospho-ERK1/2-specific antibodies in sections of a NOD.Scid mouse-expanded control HEK 
clone (Cont.), and HEK clones expressing GRK2 (GRK2) or GRK2-K220R (K220R). Nuclei were 
stained with hematoxylin (HE), bar: 50 µm. D. Nuclear phospho-ERK1/2 levels of NOD.Scid mouse-
expanded HEK clones without (Cont., set to 100 %) or with expression of GRK2 or GRK2-K220R 
(all samples were normalized to histone H2B). Data are mean ± s.d., n=3. The right panels show a 
representative immunoblot experiment. E. Increased interaction of β-arrestin with GRK2-K220R 
compared to GRK2 as determined by immuno-enrichment of GRK2 (IP) from GRK2-expressing or 
GRK2-K220R-expressing HEK clones, respectively, followed by immunoblot (IB) detection of co-
enriched β-arrestin and enriched GRK2. Bars represent mean ± s.d., n=3. The right panels show a 
representative experiment (middle, lower panels) and a control immunoblot detecting β-arrestin 
(upper panel). All results are representative of 2-3 different HEK cell clones each.  
 
FIGURE 6. Trophic effects of MEF feeder cells reconstituted GRK2-dependent growth control in 
vitro. A. Cell proliferation analysis of HEK cells plated on mitomycin-inactivated MEF feeder cells 
showed decreased cell proliferation of GRK2-expressing HEK cells compared to HEK control cells 
and enhanced cell proliferation of dominant-negative GRK2-K220R-expressing cells. As indicated, 
EGF-supplemented cells were treated without or with the MEK inhibitor PD0325901. Cell 
proliferation is expressed as percentage of control, i.e. MEK inhibitor-treated control cells (set to 100 
%). Bars represent mean ± s.d., n=3 (a,P=0.0022 and b,P=0.0018 vs. Cont. without MEK inhibitor; 
c,P=0.1515 and d,P=0.1029 vs. Cont. with MEK inhibitor). B. Nuclear phospho-ERK1/2 levels of 
HEK cells plated on mitomycin-inactivated MEF feeder cells. The left/middle panels show a 
representative experiment and the right panel presents the quantitative evaluation of three different 
experiments without MEK inhibitor (± s.d., n=3; a,P=0.0113 and b,P=0.0312 vs. Cont.).  
 
FIGURE 7. The RAF-MAPK pathway triggered by GRK2 inhibition promotes tumor growth. A. Left 
panel: Immunoblot detection of GRK2 with GRK2-specific antibodies (IB: anti-GRK2) in lysates of a 
NOD.Scid mouse-expanded control A431 tumor (Cont., lane 1), and A431 tumors expressing GRK2 
(lane 2) or GRK2-K220R (lane 3). The loading control detected β-actin (lower panel). Right panel: 
Expression level of the GRK2-specific peptide inhibitor (GRK-Inh; MAKFERLQTVTNYFITSE) in 
NOD.Scid mouse-expanded A431 tumors was determined by real-time qRT-PCR relative to mock-
transfected A431 control tumors (Cont.). Bars represent mean ± s.d. (n=4). B. Left panel: Nuclear 
phospho-ERK1/2 levels of NOD.Scid mouse-expanded A431 tumors without (Cont., set to 100 %) or 
 at H
auptbibliothek U
niversitaet Zuerich Irchel. Bereich Forschung on M
arch 10, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
GRK2 inhibition promotes tumor growth 
 16 
with expression of GRK2 (GRK2), GRK2-K220R (K220R), the GRK2-specific peptide inhibitor 
(GRK-Inh) and RKIP (RKIP), respectively (all samples were normalized to histone H2B). Data 
represent mean ± s.d., n=3 (a,P=0.0150; b,P=0.0087; c,P=0.0067; d,P=0.1537 vs. Cont). The right 
panels show a representative immunoblot experiment. C. Detection of phospho-ERK1/2 by 
immunohistology with phospho-ERK1/2-specific antibodies in a NOD.Scid mouse-expanded control 
A431 tumor (Cont.), and A431 tumors expressing GRK2, GRK2-K220R (K220R), the GRK2-specific 
peptide inhibitor (GRK-Inh) or RKIP. Nuclei were stained with hematoxylin (HE); bar: 20 µm. D. 
Real-time qRT-PCR analysis of FOS expression of different NOD.Scid mouse-expanded A431 
tumors without (Cont.) or with expression of GRK2, GRK2-K220R (K220R), the GRK2-specific 
peptide inhibitor (GRK-Inh) and RKIP. Data represent mean ± s.d. (n=3). E. Tumor mass of 
NOD.Scid mouse expanded A431 tumors without (Cont.) or with expression of GRK2 or the 
dominant-negative GRK2-K220R. Data represent mean ± s.d.; n=5 (a,P=0.0029; b,P=0.0001 vs. 
Cont.); bar 5 mm. F. GRK2 inhibition by the GRK2-specific peptide inhibitor (GRK-Inh) promoted 
A431 tumor growth whereas dual inhibition of the GRK2 and RAF-MAPK axis by RKIP did not. 
Data represent mean ± s.d.; n=5 (a,P=0.5439; b,P=0.0014 vs. Cont.); bar 5 mm. G. The expression of 
RKIP was determined by real-time qRT-PCR in NOD.Scid mouse-expanded A431 tumors expressing 
RKIP relative to A431 control tumors (Cont.). Bars represent mean ± s.d. (n=4). H. Over-expressed 
RKIP scavenged the cellular RAF1 and GRK2 pools. Enrichment of RKIP was performed with RKIP-
specific antibodies (IP: anti-RKIP) from control A431 tumors (Cont.) and RKIP-expressing A431 
tumors (RKIP) followed by immunoblot detection of enriched RKIP (upper panel), co-enriched RAF1 
(middle panel) or co-enriched GRK2 (lower panel). The left panel shows a representative experiment 
and middle/right panels present quantitative evaluation of three different experiments (mean ± s.d.; 
n=3). RKIP-bound RAF1 is expressed as % of total RAF1 (set to 100 %) and RKIP-bound GRK2 is 
expressed as % of total GRK2 (set to 100 %). Total RAF1 and total GRK2 protein was determined by 
quantitative immunoblotting. I. Tumor mass of RKIP-expressing and GRK-Inh-expressing A431 
tumors, respectively expanded in NOD.Scid mice treated without or with the MEK inhibitor 
PD0325901 (20 mg/kg/d). Data represent mean ± s.d., n=3. K. GRK-Inh expression (+GRK-Inh) did 
not significantly increase the nuclear phospho-ERK1/2 level of A431 tumors with down-regulated 
GRK2 (+siGRK2). Nuclear phospho-ERK1/2 is expressed as percentage of control, i.e. siGRK2-
expressing A431 tumors without GRK-Inh (set to 100 %). GRK2 down-regulation by siGRK2 was 
controlled by immunoblotting. Data represent mean ± s.d., n=3. L. Expression analysis of the GRK2-
regulated TGFβ target, fibronectin (FN) was performed by real-time qRT-PCR with the NOD.Scid 
mouse-expanded A431 clones used in (D). Data represent mean ± s.d. (n=3). All results are 
representative of 2-5 different A431 cell clones each. 
 
FIGURE 8. Enrichment of GRK2 by GRK2-specific peptide inhibitor immunoaffinity 
chromatography and identification by nano-LC-ESI-MS/MS. A. Proteins were enriched from GRK-
Inh-expressing tumors by immunoaffinity chromatography with antibodies specific for GRK-Inh. The 
left panel shows a silver-stained gel of proteins enriched by immunoaffinity purification with GRK2-
inhibitor-specific antibodies (AP: GRK-Inh; lane 1) compared to a control column (AP: Cont., lane 
2). The right panel shows the immunoblot (IB) detection of GRK2 in the specific eluate (lane 1) 
compared to the control eluate (lane 2). B. After immunoaffinity chromatography with GRK-Inh-
specific antibodies (AP: GRK-Inh), the GRK2-reactive band was cut and subjected to nano-LC-ESI-
MS/MS. With 27 matching peptides, the Mascot search engine identified the human beta-adrenergic 
receptor kinase 1 (GRK2) with the highest probability score. Regions of identified peptides matching 
with the human beta-adrenergic receptor kinase 1 (GRK2) protein sequence are marked. 
 
FIGURE 9. MAPK pathway activation in transgenic mice with systemic expression of the GRK2-
specific peptide inhibitor. A. Left: Generation of transgenic mouse lines (Tg1 and Tg2) with 
expression of the GRK2-specific peptide inhibitor under control of the CMV immediate–early 
promoter/enhancer (upper panel - left: diagram of the transgene; lower panel - left: identification of 
transgenic lines with integration of Tg-CMV-GRK-Inh into the mouse genome). The right panels 
present immunoblot detection of the GRK2-specific peptide inhibitor in different organs isolated from 
Tg-CMV-GRK-Inh transgenic mice. B. Immunoblot detection showed increased Fos protein level in 
different organs from transgenic mice with systemic GRK2-specific peptide inhibitor expression 
under control of the CMV promoter (Tg-GRK-Inh) compared to B6 mice. The lower panels present 
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control blots detecting β-actin. Bars represent mean ± s.d., n=3 mice/group. C, D. Nuclear (C) and 
cytosolic (D) phospho-ERK1/2 protein levels were determined by immunoblot analysis of different 
organs from transgenic mice with GRK2-specific peptide inhibitor expression under control of the 
CMV promoter. Nuclear proteins were normalized to H2B (C). Total cytosolic ERK1/2 protein was 
comparable between Tg-GRK-Inh mice and non-transgenic B6 mice (D). Bars represent mean ± s.d., 
n=3 mice/group. E, Stabilization of activated phospho-ERK1/2 by kinase-inhibited GRK2 (inhibited 
by GRK-Inh) or kinase-deficient GRK2-K220R. GRK2 protein was enriched by immunoaffinity 
purification (AP: GRK2) from A431 control tumors (Cont.) or A431 tumors expressing the GRK2-
specific peptide inhibitor (GRK-Inh, left panel), and from GRK2-expressing or GRK2-K220R-
expressing A431 tumors (right panel). Enriched GRK2 (IB: GRK2) and co-enriched phospho-ERK1/2 
(IB: p-ERK1/2) were detected in immunoblot. Quantitative assessment of co-enriched phospho-
ERK1/2 was performed and is presented as percentage of the control A431 tumor (left panel) or the 
GRK2-expressing A431 tumor (right panel). Bars represent mean ± s.d. (n=3). F. Immuno-affinity 
enrichment of GRK2 (AP: GRK2) from different organs isolated from transgenic mice with systemic 
GRK2-specific peptide inhibitor expression (Tg-GRK-Inh) or from non-transgenic B6 mice followed 
by immunoblot detection of enriched GRK2 (IB: GRK2) and co-enriched phospho-ERK1/2 (IB: p-
ERK1/2). Quantitative assessment of co-enriched phospho-ERK1/2 is presented as percentage of B6 
(±s.d., n=3 mice/group). 
 
FIGURE 10. GRK2 inhibition induced MAPK signaling in hearts of transgenic mice. A. Diagram of 
the α-MHC plasmid used for the generation of transgenic mice with myocardium-specific RKIP or 
GRK2-specific peptide inhibitor (GRK-Inh) expression. Lower panels show the identification of 
founder mice (F0) with stable integration of the respective plasmid (P) encoding the RKIP transgene 
(left) or the GRK-Inh transgene (right) into genomic DNA. B. Immunoblot analysis revealed 
increased RKIP protein in cardiac tissue of transgenic Tg-RKIP mice (left), and the GRK-specific 
peptide inhibitor was detected in cardiac tissue of transgenic Tg-GRK-Inh mice (right). Bars represent 
mean ± s.d., n=3 mice/group (a,P=0.0102; b,P=0.0125; c,P=0.0028; d,P=0.0035 vs. B6, set to 1), and 
lower panels show representative immunoblots. C. Microarray gene expression profiling identified 
significantly regulated probe sets (P≤0.01, -fold change relatve to B6 mice ≥2 or ≤ -2, and signal 
intensity ≥100) in hearts of 2 month-old Tg-RKIP and Tg-GRK-Inh mice, respectively, relative to 
age-matched non-transgenic B6 control mice. The Venn diagram (left) illustrates the number of 
significantly regulated probe sets for each model. Thirty-seven probe sets (i.e. 61.7 %) of Tg-RKIP 
hearts showed concordant regulation with Tg-GRK-Inh mice. Right panel: Data filtering identified 
probe sets with significant up-regulation in Tg-GRK-Inh hearts (≥2-fold over the B6 control; P≤0.01), 
and reduced expression in Tg-RKIP hearts relative to B6. D. The Fos protein was increased in Tg-
GRK-Inh hearts relative to B6 controls whereas Fos was decreased in Tg-RKIP hearts. Bars represent 
mean ± s.d., n=3 mice/group (a,P=0.0184; b,P=0.0284; c,P=0.0179; d,P=0.0137 vs. B6, set to 1), and 
lower panels show representative immunoblots. E. Immunohistology detection revealed a high RKIP 
protein level in a heart section of a Tg-RKIP mouse relative to an age-matched B6 control mouse or a 
GRK2-specific peptide inhibitor-expressing mouse (Tg-GRK-Inh). Nuclei were stained with 
hematoxylin (HE), bar: 40 µm. F. Immunohistology detection of phospho-ERK1/2 in heart sections of 
Tg-RKIP, B6 control and Tg-GRK-Inh mice (bar: 40 µm). Histology data are representative of three 
different mice each (E,F). G. Increased nuclear phospho-ERK1/2 level of transgenic hearts with 
GRK2-specific peptide inhibitor expression. The left panels show a representative immunoblot 
experiment, and the right panel presents quantitative data (± s.d., n=3 mice/group; a,P=0.0099; 
b,P=0.0132; vs. B6, set to 100 %). H. Transgenic RKIP scavenged the cardiac Raf1 and GRK2 protein 
pools as determined by immuno-enrichment of RKIP with RKIP-specific antibodies (IP: RKIP) from 
B6 hearts (B6) and RKIP-transgenic hearts (Tg-RKIP) followed by immunoblot detection of enriched 
RKIP (upper panel), co-enriched Raf1 (middle panel) and co-enriched GRK2 (lower panel). The left 
panels show a representative experiment and middle/right panels represent quantitative evaluation of 
three different experiments. Raf1 bound to RKIP is expressed as % of total Raf1, and GRK2 bound to 
RKIP is expressed as % of total GRK2 (±s.d., n=3).  
 
FIGURE 11. Concordant regulation of gene expression by RKIP and the GRK2-specific peptide 
inhibitor in hearts of transgenic mice. Whole genome microarray gene expression profiling of heart 
tissue from 2 month-old mice identified probe sets of RKIP-transgenic hearts (Tg-RKIP) and GRK-
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Inh-transgenic hearts (Tg-GRK-Inh) with concordant up-regulation (upper panel) or down-regulation 
(lower panel) compared to B6 control mice (-fold change relative to B6: ≥2 or ≤-2, and P≤0.01). Bars 
represent mean of two different gene chips (three mice/gene chip). All data were normalized to beta 
actin. 
 
FIGURE 12. Inhibition of the MAPK pathway by transgenic RKIP over-expression triggered signs of 
heart failure in B6 mice. A. Quantitative assessment of TUNEL-positive nuclei, determination of 
heart weight to body weight ratio (HW/BW, mg/g), and measurement of left ventricular ejection 
fraction (%) by transthoracic echocardiography of Tg-RKIP, B6 control and Tg-GRK-Inh mice (age: 
5 months). Data represent mean ±s.d., n=5 mice/group (a,P=0.0001; b,P=0.0018; c,P=0.0001; 
d,P=0.0352 vs. B6). B. Representative hematoxylin-eosin (H&E)-stained heart sections of 5 month-
old Tg-RKIP, B6 and Tg-GRK-Inh mice (bar: 2 mm). C. TUNEL staining of heart sections from Tg-
RKIP, B6 control and Tg-GRK-Inh mice (bar: 20 µm). D. Five month-old mice with myocardium-
specific RKIP over-expression showed cardiac lipid overload as detected by oil red O staining (bar: 
40 µm). E. Gene expression analysis by real-time qRT-PCR detected increased expression of lipid 
metabolism genes (Scd1, Fasn, Ucp1, Retn) in hearts of 5 month-old RKIP-transgenic mice (all 
samples were normalized to Gapdh). Bars represent mean ± s.d. (n=3). P values of significantly 
different gene expression data (vs. B6) are indicated. F. Quantitative assessment of TUNEL-positive 
nuclei of neonatal mouse cardiomyocytes isolated from transgenic hearts with GRK2-specific peptide 
inhibitor expression (Tg-GRK-Inh) or from RKIP-transgenic hearts. The left panel shows the 
percentage of TUNEL-positive cardiomyocytes (±s.d., n=3), and middle/right panels show 
representative images. G. Treatment of neonatal mouse cardiomyocytes with the MEK-specific 
inhibitor PD0325901 (MEK-Inh) increased the number of TUNEL-positive neonatal mouse 
cardiomyocytes from B6 mice whereas RKIP-transgenic cardiomyocytes were not substantially 
affected (±s.d., n=3). Histology experiments are representative of three different mice each (B,C,D). 
 
FIGURE 13. Inhibition of GRK2 in transgenic FVB mice. A. Quantitative assessment of TUNEL-
positive nuclei, determination of heart weight to body weight ratio (HW/BW, mg/g), and 
measurement of left ventricular ejection fraction (%) by transthoracic echocardiography of FVB mice 
with myocardium-specific RKIP expression, and non-transgenic FVB control mice (age: 10 weeks). 
Data represent mean ±s.d., n=5 mice/group (a,P=0.0001; b,P=0.0004; c,P<0.0001). B. Representative 
hematoxylin-eosin (H&E)-stained heart sections of a 10 week-old FVB mouse with transgenic RKIP 
expression (Tg-RKIP, FVB) and a non-transgenic FVB control mouse show cardiac hypertrophy with 
dilatation of the RKIP-transgenic FVB mouse (bar: 1.8 mm). C. Increased cardiac RKIP protein level 
of two different FVB mouse lines with myocardium-specific RKIP expression (± s.d., n=5 
mice/group; a,P=0.0025; b,P=0.0003 vs. FVB). D. Cardiac GRK2-specific peptide inhibitor detection 
in FVB mice with transgenic GRK-Inh expression (± s.d., n=5 mice/group; a,P=0.0031; b,P=0.0004 
vs. FVB). E. Representative hematoxylin-eosin (H&E)-stained heart sections of 4 month-old FVB 
mice with transgenic GRK2-specific peptide inhibitor expression (Tg-GRK-Inh, FVB; left panel) and 
non-transgenic FVB control mice (right panel) without (Sham) or with 4 weeks of AAC (bar: 1.8 
mm). F. Determination of heart weight to body weight ratio (HW/BW) and left ventricular ejection 
fraction (%) by transthoracic echocardiography of Tg-GRK-Inh (FVB) mice and non-transgenic FVB 
mice without (Sham) and with pressure overload imposed by 4 weeks of AAC. Data represent mean 
±s.d., n=4 mice/group (a,P=0.0201 vs. Sham-Tg-GRK-Inh; b,P=0.0033 vs. AAC-FVB; c,P=0.0002 vs. 
Sham FVB; d,P=0.0001 vs. Sham-Tg-GRK-Inh; e,P=0.0004 vs. AAC-FVB; f,P<0.0001 vs. Sham 
FVB). Histology experiments are representative of three different mice each (B,E). 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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Figure 9 
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Figure 10 
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Figure 11 
 
 
 
 at H
auptbibliothek U
niversitaet Zuerich Irchel. Bereich Forschung on M
arch 10, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
GRK2 inhibition promotes tumor growth 
 30 
Figure 12 
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Figure 13 
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